VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CME
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CMECME Group Inc.
$311.56$111.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCMECash Flow

CME Group Inc. (CME) Cash Flow Statement

26Y historyFree accessUpdated daily

Operating cash flow converted at an average 1.03x net income across nine reported quarters, though capital returns — $2.7B of dividends in 2026Q1 and $698.2M of buybacks in 2026Q2 — appear to outpace single-quarter operating generation of roughly $1.1B.

Income StatementBalance SheetCash FlowRatios

CME Cash Flow Statement

Annual statement

CME Cash Flow Statement

CME Group Inc. (CME) cash flow statement — 26-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00
Cash from Operations4.43B4.28B3.69B3.45B3.06B2.4B2.72B2.67B2.44B1.84B1.72B1.52B1.29B1.28B1.22B1.35B1.36B1.08B1.2B814.37M471.7M391.59M328.81M191.15M141.14M120.57M32.97M
Operating CF Growth %25.87%15.89%6.85%13.02%27.21%-11.53%1.6%9.51%32.62%7.25%13.24%17.34%0.85%5.24%-9.62%-0.74%25.23%-9.53%47.01%72.65%20.46%19.1%72.02%35.43%17.06%265.7%-
Net Income4.4B4.07B3.53B3.23B2.69B2.64B2.11B2.12B1.96B4.06B1.53B1.25B1.13B978.1M906.7M1.81B952.1M825.8M715.49M658.53M407.35M306.86M219.56M122.13M94.07M68.3M-5.91M
Depreciation & Amortization249.9M330.9M336.8M352.6M362.6M385.4M464.4M473.3M248.7M208.5M225.3M228.6M233.2M238.1M253.1M260.5M258M251.4M238.37M142.69M75.32M68.22M56.93M53.02M48.51M37.64M33.49M
Deferred Taxes13.1M-6.1M-66.4M-75M-23.2M34.8M-41.6M-3.7M114.3M-2.36B-83M63.3M78.9M-6M82.2M-658.7M22.3M-56.9M-115.11M-50.58M-24.85M-3.25M4.26M3.31M-5.64M-8.88M811K
Other Non-Cash Items-299.2M-314.4M-3.6M-37.7M36.5M-568.1M31.2M48.9M-32.1M-115M-23.3M70.8M-2.3M31.2M-84.6M20.8M44.4M61.2M361.78M36.86M6.92M59.05M65.48M7.4M4.04M17.22M7.31M
Working Capital Changes-28.4M99.7M-191.6M-95.2M-95.2M-161.8M59.2M-34.6M49.7M-16.7M-3.3M-155.2M-200.1M-15.3M-2M-142M38.7M-31.8M-34.88M4.03M-9.4M-39.29M-17.42M5.29M163K6.29M-2.73M
Cash from Investing1.48B1.5B-82.6M20.9M-489.8M58.4M-175.5M-152.6M-1.89B179.9M53.7M17.9M-199.1M190.5M-206M-153.6M-108.4M544.8M-3.75B-78.64M-85.86M-82.33M-125.84M-327.05M34.35M-78.22M-12.95M
Purchase of Investments-10.9M-6M-4.5M-4.1M-4.4M-7.8M-11.1M-15.4M-10M-3M-45.9M-35.3M-38.3M-36.6M-32.5M-10.2M-10.2M-159.9M-367.55M-129.13M-44.77M-70.06M-120.18M-256.42M-43.96M-286.54M-43.12M
Sale/Maturity of Investments6.5M7.9M6M5.9M6.3M9.4M12.3M18.8M11.8M266.1M191.7M184.1M37.5M164.3M5.1M11.3M59.1M865.7M375.2M203.8M73.67M75.23M68.33M0137.72M240M59.52M
Net Investment Activity-4.4M1.9M1.5M1.8M1.9M1.6M1.2M3.4M1.8M263.1M145.8M148.8M-800K127.7M-27.4M1.1M48.9M705.8M7.65M74.68M28.9M5.17M-51.85M-256.42M93.77M-46.54M16.4M
Acquisitions1.58B1.58B9.9M95.5M-402M144.7M20.8M89.6M-1.77B-1.3M-300K-16.7M-59.3M-4M-188.3M172.2M-37M0-3.48B116.01M-20.23M0000011.17M
Other Investing-6.8M000039.3M000261.8M145.5M7M1.7M192.4M151.5M-154.7M39.7M-3.1M-80.58M-105.68M-6.71M-1.87M-6.49M-7.62M-3.07M-15.38M-29.35M
Cash from Financing-18.5M56.51B5.08B-48.34B-25.38B69.91B-2.46B-2.34B-1.08B-1.99B-1.59B-1.21B-2.2B-606M-448.4M-1.01B-653.4M-1.67B2B-859.93M-27.22M-55.93M-30.53M-18.23M94.67M-3.9M-3.61M
Dividends Paid-4.09B-3.93B-3.58B-3.24B-2.63B-2.19B-2.11B-1.7B-2.15B-1.99B-1.79B-1.34B-1.5B-599.1M-1.22B-372.8M-912.8M-305.6M-615.19M-151.58M-87.54M-63.26M-35.07M-20.63M-17.29M00
Share Repurchases-2.02B-266.1M-33M-21.4M-24.8M0-41.4M-36.8M0000000-220.4M-575.3M-27M-224.03M-949.34M0000000
Stock Issued00000965M036.8M398.4M36.7M51.8M64M0000607.1M011.37M40.41M16.43M7.33M6.05M7.88M117.46M00
Net Stock Activity-2.02B-266.1M-33M-21.4M-24.8M965M-41.4M0398.4M36.7M51.8M64M000-220.4M31.8M-27M-212.66M-908.93M16.43M7.33M6.05M7.88M117.46M00
Debt Issuance (Net)0-1000K0-1000K-1000K0-1000K-1000K1000K001000K-1000K-1000K1000K-1000K1000K-1000K1000K1000K01000K-1000K-1000K-1000K-1000K-1000K
Other Financing6.08B60.72B8.69B-45.07B-22.71B71.13B-2.2M53.6M-447.9M-28.5M11.7M83.2M-2.4M-79.3M6.1M8.1M19.5M-432.5M-85.65M37.73M43.88M-7.33M00000
Net Change in Cash8.82B62.29B8.68B-44.86B-22.82B72.37B81.9M179.4M-528.8M35M176M326.5M-1.1B865M562.4M187.1M594.6M-37.3M-547.42M-124.19M358.61M253.33M172.44M-154.14M270.16M38.45M16.41M
Exchange Rate Effect2.93B00000000000000000000000000
Cash at Beginning2.15B101.79B93.11B137.97B160.79B88.42B1.56B1.38B1.91B1.87B1.69B1.37B2.47B1.6B1.04B855.2M260.6M297.9M845.31M969.5M610.89M357.56M185.12M339.26M69.1M30.66M14.25M
Cash at End2.2B164.08B101.79B93.11B137.97B160.79B1.64B1.56B1.38B1.9B1.87B1.69B1.37B2.47B1.6B1.04B855.2M260.6M297.89M845.31M969.5M610.89M357.56M185.12M339.26M69.1M30.66M
Interest Paid140.4M135.6M129.9M129.9M133.2M133.3M133.3M146.3M108.3M84.8M84.8M89.1M111.4M133.4M110.6M111.9M104.9M90.8M21.1M00000000
Income Taxes Paid1.33B1.16B1.2B1.11B973.4M755M652.7M591.2M577.4M762.8M706.7M716.6M641.5M612.2M624.4M816.1M765.9M629.7M665.4M00000000
Free Cash Flow4.33B4.19B3.6B3.38B2.97B2.28B2.52B2.43B2.32B1.76B1.62B1.4B1.15B1.15B1.07B1.17B1.2B925.2M997.1M650.73M383.89M305.97M261.31M128.13M84.8M104.27M21.8M
FCF Growth %6.1%16.6%6.49%13.86%30.38%-9.65%3.75%4.44%32.16%8.27%15.92%21.76%-0.36%7.43%-8.44%-1.86%29.31%-7.21%53.23%69.51%25.47%17.09%103.94%51.11%-18.67%378.31%-

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Variable dividend outflow concentration

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Backed by Cash Conversion

CME's operating cash flow converted at an average 1.03x ratio to net income across the nine quarters with available data, indicating reported earnings are substantively cash-backed despite the exchange's non-standard cash dynamics, according to CME's reported statements.

The conversion ratio has held in a tight 0.88x-1.17x band, with the 2024Q2 trough of 0.88x ($776.9M OCF against $883.2M net income) proving transient rather than indicative of deteriorating earnings quality. Notably, essentially zero long-term debt issuance and no short-term debt movement across the full ten quarters implies that both regulatory buffer maintenance and the escalating shareholder distributions appear to be funded internally rather than through leverage. Because clearing collateral movements flow through operating cash at an exchange, the stability of this ratio suggests those flows are roughly self-neutralizing quarter to quarter, though the pattern warrants continued monitoring if collateral requirements tighten.

Variable Dividend Absorbs Cash Surplus

CME's dividend outflow jumped from approximately $418.5M per quarter in 2024 to $2.7B in 2026Q1 under its variable policy, while buybacks accelerated to $698.2M in 2026Q2, a combined pace that appears to exceed single-quarter operating generation, as reported in CME's cash flow statements.

Adding Q1 and Q2 2026 distributions and repurchases yields roughly $4.4B of cash returned against approximately $2.2B of operating cash flow for the same two quarters, which may indicate the variable component is being settled from accumulated balance-sheet cash rather than current-period generation. The buyback trajectory is arguably the more revealing signal: repurchases were negligible through 2024 (never above $17.1M) but stepped up to $538.7M and $698.2M in the first two quarters of 2026, suggesting management views the equity as attractively valued at current earnings levels rather than prioritizing balance-sheet accumulation. With no debt issuance to lean on, sustainability of this pace appears contingent on volumes sustaining the record levels seen in H1 2026.

Provision Spike Skews Cash Read

CME's credit loss provision surged to $568.3M in 2026Q2, more than triple the $165M-$197M quarterly range maintained through 2024-2025, then fell to $60.7M in Q3, a swing that complicates interpretation of reported operating cash conversion, per CME's recent figures.

The striking detail is that 2026Q2 operating cash flow of $947.1M still converted at 0.91x of net income despite the $568.3M provision charge, implying the reserve build was largely non-cash and reversed back through operating activities rather than consuming liquidity in the period. This suggests the charge reflects a balance-sheet reservation against clearing-member or counterparty exposure rather than an actual funded loss, which would be consistent with the normalization to $60.7M in Q3. Investors should treat the aggregate OCF/NI ratio as insufficient evidence of credit cost durability here, since a reserve release in a future quarter could mechanically flatter conversion without any change in underlying exposure.

Securities Flows Immaterial to Cash

Investment purchases and sales never exceeded $3.4M and $15.1M respectively in any reported quarter, meaning securities portfolio turnover contributes essentially nothing to CME's investing cash flow line across the ten-quarter window, as shown in CME's quarterly statements.

The near-zero investing activity means the cash flow statement offers little analytical purchase on reinvestment rates, duration positioning, or the mark-to-market trajectory of the securities book, all of which would need to be assessed from the balance sheet and footnote disclosures instead. For a business whose interest income recently swung from consistently negative net interest income to $1.7B, this apparent absence of portfolio activity suggests the interest-bearing assets driving that income may sit in categories not captured in this line item, warranting further investigation. The single negative sale figure in 2024Q4 (-$12.4M) is an outlier too small to carry analytical weight on its own.

Cash Statement Obscures Structural Shifts

All 2026Q3 cash flow lines report $0 including operating cash flow, dividends, and buybacks, which should be treated as data unavailable rather than a cessation of activity, given that CME reported $1.0B of net income in the same quarter, according to CME's filings.

The cash flow presentation also offers no visibility into the abrupt net interest income discontinuity identified in the income statement analysis, where NII moved from a consistent -$40M to -$44M range to $1.7B in 2025Q4 and $1.4B in 2026Q3, leaving the cash interest dynamics behind that swing unexamined. Additionally, the pronounced Q1 dividend spikes ($2.6B in 2025Q1, $2.7B in 2026Q1) versus modest Q4 payments create a timing mismatch between accrued earnings and cash distribution that can distort any single-quarter comparison of retained capital. Together with the record H1 volumes coexisting with an EPS miss, these features suggest the cash flow statement alone may understate both the quality and the volatility of CME's earnings, and should be triangulated against balance-sheet collateral and interest-bearing deposit balances.

CME — Frequently Asked Questions

Quick answers to the most common questions about buying CME stock.

How much cash does CME Group Inc. (CME) generate from operations?

CME Group Inc. (CME) generated $4.28B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is CME Group Inc.'s free cash flow?

CME Group Inc. (CME) generated $4.19B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is CME Group Inc.'s capital expenditure (CapEx)?

CME Group Inc. (CME) spent $83.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does CME Group Inc. distribute cash to shareholders?

In 2025, CME Group Inc. (CME) returned $3.93B to shareholders via cash dividends and spent $266.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.